ReviewCancer medicine2021
Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
Review in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review.Journal of cancer research and clinical oncology · 2023Pooled it
- The Female Reproductive Microbiome: Mechanistic Insights and Bioengineering Perspectives.Biology · 2026Review
- Impact of vitamin D plasma levels on in vitro natural killer cell cytotoxicity against non-small cell lung carcinoma in the presence of nivolumab.Internal and emergency medicine · 2026Article
- Redox signaling in the heart and brain: the roles of nitric oxide and reactive oxygen species in disease and therapy.Metabolic brain disease · 2026Review
- Evaluation of the antibacterial activity of Akkermansia muciniphila extract against Enterococcus faecium isolates.Molecular biology reports · 2026Article
- Unraveling the microbial landscape in prostate cancer: pathogenesis to therapy.NPJ biofilms and microbiomes · 2026Review
- Biliary stents can modify the microbiota and promote the progression of pancreatic cancer.Frontiers in oncology · 2026Review
- Mechanisms and therapeutic strategies for immunotherapy resistance in gastric cancer.Cancer cell international · 2025Review
- Characterization of intra-tumoral microbiota from transcriptomic sequencing of Asian breast cancer.Scientific reports · 2025Article
- Mathematical Modeling and Association Analysis Decipher the Impact of the Gut Microbiome on Cancer Immunotherapy.Cancer research · 2025Article
- The East Asian gut microbiome and its role in oncology: a narrative review.Singapore medical journal · 2025Review
- Biometric Strategies to Improve Vaccine Immunogenicity and Effectiveness.Biomimetics (Basel, Switzerland) · 2025Review
- Innovative Immunotherapy and Its Transformative Impact on Gastric Adenocarcinoma: A Comprehensive Review of the Disease's Origins, Epidemiology, Classification, Diagnosis, and Treatment Options.ACS pharmacology & translational science · 2025Review
- A Literature Review on the Impact of the Gut Microbiome on Cancer Treatment Efficacy, Disease Evolution and Toxicity: The Implications for Hematological Malignancies.Journal of clinical medicine · 2025Review
- Beneficial Probiotics with New Cancer Therapies for Improved Treatment of Hepatocellular Carcinoma.Diseases (Basel, Switzerland) · 2025Review
- NK Cell-Microbiota Interaction Biomarker Strategy: Advancing Prostate Cancer Management.Biomolecules · 2025Review
- Deciphering the urinary microbiome and urological cancers: from correlation to mechanisms and treatment.Frontiers in microbiology · 2025Review
- Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy.Frontiers in immunology · 2025Review
- Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor.International journal of clinical oncology · 2024Article
- Effect of Chemotherapy onIndian journal of microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human gastrointestinal (GI) tract harbors gut microbiome, which plays a crucial role in preserving homeostasis at the intestinal host-microbial interface. Conversely, specific gut microbiota may be altered during various pathological conditions and produce a number of toxic compounds and oncoproteins, in turn, to induce both inflammatory response and carcinogenesis. Recently, promising findings have been documented toward the implementation of certain intestinal microbiome in the next era of cancer biology and cancer immunotherapy. Notably, intestinal microbiota can cooperate with immune checkpoint inhibitors (ICIs) of its host, especially in enhancing the efficacy of programmed death 1 (PD-1) protein and its ligand programmed death ligand 1 (PD-L1) blockade therapy for cancer. Herein, we review the dual function of gut microbiota in triggering GI cancers, its association with host immunity and its beneficial functions in modulation of cancer immunotherapy responses. Furthermore, we consider the significance of gut microbiota as a potential biomarker for predicting the efficacy of cancer immunotherapy. Finally, we summarize the relevant limitations that affect the effectiveness and clinical applications of gut microbiome in response to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.